NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

Phase 1

Completed

Conditions: Avian Influenza
Influenza

Interventions: Drug: AS03
Drug: MF59 adjuvant
Biological: Monovalent Influenza A/H5N8 vaccine

First Posted Date: 2015-12-08

Last Posted Date: 2019-10-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 276

Registration Number: NCT02624219

Locations: 🇺🇸
University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States
🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States
🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States

and more 1 locations

Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia

Phase 1

Completed

Conditions: Acute Falciparum Malaria

Interventions: Drug: Dihydroartemisinin-piperaquine (DHA-PPQ)
Drug: Mefloquine (MQ)

First Posted Date: 2015-11-24

Last Posted Date: 2019-10-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 216

Registration Number: NCT02612545

Locations: 🇰🇭
National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H, Phnom Penh, Cambodia

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

Phase 2

Terminated

Conditions: Healthy Participants
Rheumatoid Arthritis (RA) Prevention

Interventions: Drug: HCQ Placebo
Drug: Hydroxychloroquine

First Posted Date: 2015-11-11

Last Posted Date: 2023-12-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 144

Registration Number: NCT02603146

Locations: 🇺🇸
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, United States
🇺🇸
University of Nebraska Medical Center: Division of Rheumatology, Omaha, Nebraska, United States
🇺🇸
Cedars Sinai Medical Center: Division of Rheumatology, Los Angeles, California, United States

and more 11 locations

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: Placebo
Biological: D46cpΔM2-2 vaccine

First Posted Date: 2015-11-10

Last Posted Date: 2020-03-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT02601612

Locations: 🇺🇸
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

Phase 1

Completed

Conditions: Neutralizing Antibody
Prevention of HIV Infection
HIV Antibodies
Monoclonal Antibody, Human

Interventions: Biological: VRC-HIVMAB080-00-AB (VRC01LS)
Biological: VRC-HIVMAB060-00-AB (VRC01)

First Posted Date: 2015-11-09

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 49

Registration Number: NCT02599896

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2

Interventions: Other: Live recombinantly derived A/Bethesda/MM1/H3N2 virus

First Posted Date: 2015-11-03

Last Posted Date: 2019-12-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 49

Registration Number: NCT02594189

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: Placebo for VRC01
Biological: VRC01
Drug: Antiretroviral therapy (ART) (regimen will vary within countries and by patient)

First Posted Date: 2015-10-29

Last Posted Date: 2021-11-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT02591420

Locations: 🇹🇿
National Institute for Medical Research (NIMR)-Mbeya Medical Research Center (MMRC) Non-Network CRS, Mbeya, Tanzania
🇹🇭
ECHO Center Non-Network CRS, Chonburi, Thailand
🇰🇪
Kenya Med. Research Inst./Walter Reed Project, Clinical Research Centre, Off Hospital Road. Kericho, Kericho, Kenya

and more 2 locations

H7N9 Boost in Healthy Adults

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Monovalent influenza A/H7N9 virus vaccine

First Posted Date: 2015-10-26

Last Posted Date: 2018-08-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT02586792

Locations: 🇺🇸
Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States

Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis

Phase 2

Completed

Conditions: HIV Infections
Tuberculosis

Interventions: Drug: Bedaquiline
Drug: Delamanid
Drug: Dolutegravir
Drug: Multidrug Background Treatment (MBT) for TB

First Posted Date: 2015-10-21

Last Posted Date: 2022-01-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 84

Registration Number: NCT02583048

Locations: 🇵🇪
Barranco CRS, Lima, Peru
🇿🇦
Task Applied Science (TASK) CRS, Cape Town, Western Cape Province, South Africa
🇿🇦
South African Tuberculosis Vaccine Initiative (SATVI) CRS, Cape Town, Western Cape Province, South Africa

Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

Phase 3

Completed

Conditions: Influenza A Virus Infection

Interventions: Biological: High-titer anti-influenza plasma
Biological: Low-titer anti-influenza plasma

First Posted Date: 2015-10-09

Last Posted Date: 2019-06-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 138

Registration Number: NCT02572817

Locations: 🇺🇸
Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
UCLA Pediatrics Infectious Diseases, Los Angeles, California, United States

and more 27 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy